Background and objective Clinical guidelines discourage antibiotic prescribing for many acute respiratory infections (ARIs), especially for nonantibiotic appropriate diagnoses. Electronic health record (EHR)-based clinical decision support has the potential to improve antibiotic prescribing for ARIs. Methods We randomly assigned 27 primary care clinics to receive an EHR-integrated, documentationbased clinical decision support system for the care of patients with ARIs -the ARI Smart Form -or to
Introduction
Acute respiratory infections (ARIs) -including nonspecific upper respiratory infections, otitis media, sinusitis, pharyngitis, acute bronchitis, pneumonia and influenza -are the most common symptomatic reason for seeking ambulatory care in the USA, accounting for approximately 7% of visits. 1 ARIs are also the number one reason for antibiotic prescribing in the USA, accounting for about 50% of antibiotic prescriptions to adults. 2 Guidelines and reviews from the USA and internationally generally discourage antibiotic prescribing for ARIs, [3] [4] [5] [6] [7] [8] but much antibiotic prescribing for ARIs is inappropriate due to prescribing antibiotics for viral conditions or prescribing unnecessarily broad-spectrum antibiotics. [9] [10] [11] Inappropriate antibiotic prescribing increases medical costs, increases the prevalence of antibiotic resistant bacteria, and needlessly exposes patients to adverse drug events. 12, 13 Electronic health records (EHRs) with clinical decision support have shown potential for improving the quality of medical care, mainly through the use of prescribing alerts and preventive care reminders. 14 Improving care for ARIs through decision support may be more challenging than for chronic problems, because the quality problem is an error of commission, decision support must be delivered during patient visits and ARI visits are typically brief. 15, 16 We designed an EHR-integrated, documentationbased clinical decision support system for the care of patients with ARIs, the ARI Smart Form. We designed the ARI Smart Form with two principal objectives: to assist clinicians in reducing inappropriate antibiotic prescribing and to improve workflow for clinicians. We have previously reported results of usability testing and pilot testing, which showed the potential of the ARI Smart Form to be incorporated into clinical practice and reduce inappropriate antibiotic prescribing. 17, 18 To evaluate the ARI Smart Form in actual practice, we conducted a cluster randomised controlled trial in primary care clinics.
Methods

Setting and EHR
Partners HealthCare System is an integrated regional healthcare delivery system in eastern Massachusetts. The main EHR used in Partners HealthCare ambulatory clinics is the longitudinal medical record, or LMR. The LMR is an internally developed, full featured EHR, approved by the Certification Commission for Healthcare Information Technology and including; primary care and subspecialty notes; problem lists; medication lists; coded allergies; and laboratory test and radiographic study results. 19 The ARI Smart Form
The ARI Smart Form has been described previously. 17, 18 Briefly, the ARI Smart Form is an LMR module that is launched from the notes page of the EHR and is designed to be used while interviewing and evaluating patients. The ARI Smart Form includes six components: entry of clinical information; patient data display; diagnosis selection; presentation of treatment options with integrated decision support; printing of patient handouts and access to supporting medical literature. The ARI Smart Form imports patients' problem lists, allergies, medications and vital signs by clinic). For antibiotic appropriate ARI diagnoses, the antibiotic prescribing rate was 54% in the intervention clinics and 59% in the control clinics (OR, 0.8; 95% CI, 0.5-1.3). For non-antibiotic appropriate diagnoses, the antibiotic prescribing rate was 32% in the intervention clinics and 34% in the control clinics (OR, 0.9; 95% CI, 0.6-1.4). When the ARI Smart Form was used, based on diagnoses entered on the form, the antibiotic prescribing rate was 49% overall, 88% for antibiotic appropriate diagnoses and 27% for non-antibiotic appropriate diagnoses. In an as-used analysis, the ARI Smart Form was associated with a lower antibiotic prescribing rate for acute bronchitis (OR, 0.5; 95% CI, 0.3-0.8).
Conclusions The ARI Smart Form neither reduced overall antibiotic prescribing nor significantly improved the appropriateness of antibiotic prescribing for ARIs, but it was not widely used. When used, the ARI Smart Form may improve diagnostic accuracy compared to administrative diagnoses and may reduce antibiotic prescribing for certain diagnoses.
Keywords: antibacterial agents, computerised medical record systems, clinical decision support systems, respiratory tract infections into the visit note; speeds workflow using drop-down lists, radio buttons and check boxes; and provides 'one-click' ordering of medicines, patient handouts, and excuse-from-work letters. The ARI Smart Form automatically generates a narrative visit note that would usually meet Evaluation and Management criteria for a Level 4 visit (moderate severity on a one to five scale).
The ARI Smart Form provides decision support in several ways. First, clinicians' selection of a particular ARI diagnosis results in the generation of a diagnosis appropriate order set. Antibiotic prescribing and antibiotic choices are based on the recommendations of the Centers for Disease Control and Prevention (CDC) and the American College of Physicians (ACP). 8 At a basic level, the ARI Smart Form decision support strives to make the antibiotic treatment match the diagnosis (e.g. not prescribing antibiotics for patients with acute bronchitis). Second, the ARI Smart Form provides diagnostic decision support by calculating the probability of streptococcal pharyngitis based on signs and symptoms entered by the clinician, and also how rapid streptococcal testing will change the probability of streptococcal pharyngitis. 20 Third, the ARI Smart Form has medication prescribing alerts regarding potential medication interactions or patient allergies. Fourth, the ARI Smart Form supports clinicians by providing easy access to diagnosis appropriate patient handouts. The handouts contain information about the diagnosis and why antibiotics may or may not be indicated. Mainly through the use of diagnosis appropriate order sets, we strove to make it easy for clinicians to follow ARI antibiotic prescribing guidelines. 21 
Clinic matching and randomisation
We randomly assigned 27 primary care clinics associated with Partners HealthCare that use the LMR to participate in the study. With the exception of a single clinic that was randomly assigned on its own, clinics were matched on the basis of size. Matched pairs were randomised simultaneously, with one practice from each pair assigned to receive the intervention and the other assigned to offer usual care. 
Intervention and implementation
Outcomes
The primary outcome was the antibiotic prescribing rate for ARI visits, based on electronic prescribing using the EHR, using an intent-to-intervene analysis. We had previously found that EHR based antibiotic prescribing had a sensitivity of 43%, but was increasing rapidly over time, from 22% in 2000 to 58% in 2003. 22 During the intervention period, it was the policy of study clinics that all prescriptions be written using the EHR. We defined antibiotic use as the prescription of an orally administered antibiotic agent within three days of an ARI visit. Secondary outcomes included antibiotic prescribing for antibiotic appropriate diagnoses, non-antibiotic appropriate diagnoses and individual ARI diagnoses; the 30-day revisit rate; and the 30-day revisit rate attributable to ARIs (i.e. a second visit within 30 days of the index ARI visit with another ARI diagnosis). We also performed as-used analyses, comparing antibiotic prescribing rates in clinic visits in which the ARI Smart Form was used to visits in the control clinics.
Data collection and analysis
We examined baseline characteristics of the control and intervention clinics and clinicians. We identified ARI visits using administrative data coded using the International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) codes. ARI visits were those with any ICD-9-CM code for non-specific upper respiratory infections (ICD-9-CM 460, 464 and 465), otitis media (ICD-9-CM 381 and 382), sinusitis (ICD-9-CM 461 and 473), pharyngitis (streptococcal and non-streptococcal; ICD-9-CM 034.0, 462 and 463), acute bronchitis (ICD-9-CM 466 and 490), influenza (ICD-9-CM 487) and pneumonia (ICD-9-CM 481-486). These administrative data have a sensitivity of 98%, specificity of 96% and positive predictive value of 96% compared with medical record review. 22 We considered otitis media, sinusitis, streptococcal pharyngitis, and pneumonia to be antibiotic appropriate diagnoses. We considered non-specific upper respiratory tract infections, non-streptococcal pharyngitis, acute bronchitis and influenza to be non-antibiotic appropriate diagnoses.
During the intervention, we measured the number of visits, the number of ARI visits and, for clinicians in the intervention practices, whether clinicians ever used the ARI Smart Form. Using registration data, we examined patient age, gender, race/ethnicity, primary language, primary insurance and mean income by zip code. For intervention visits at which the ARI Smart Form was used, we recorded the duration of use (i.e. the amount of time between opening and submitting the ARI Smart Form).
Statistical analysis and power calculation
We used standard descriptive statistics to compare clinicians and patients. To account for the level of randomisation, we adjusted all statistical analysesthe chi-squared test for categorical variables and Student's t-test for continuous variables -for clustering by practice using PROC GENMOD in SAS version 9.1 (SAS Institute Inc., Cary, NC). For visits in which the ARI Smart Form was used, we used chancecorrected k with 95% confidence intervals to assess the degree of agreement between the ICD-9 diagnosis and the ARI Smart Form listed diagnosis. 23 We considered two-sided P values < 0.05 significant. Assuming a baseline antibiotic prescribing rate for ARIs of 35%, of 0.05 and an intra-class correlation coefficient of 0.10, 1798 visits in each group were required to have 80% power to detect a 7% absolute reduction in the antibiotic prescribing rate. 22 
Results
Clinic, clinician and patient characteristics
Prior to the intervention, there were no differences between the intervention and control clinics in duration of EHR use, overall antibiotic prescribing rates or ARI antibiotic prescribing rates (data not shown). During the seven-month intervention period, there were 214 900 visits by 111 820 patients to 443 clinicians in the 27 control and intervention practices (Figure 1 ). There were no significant differences in the clinicians or the patients between the control and intervention clinics (Table 1 and Table 2 ). There was no difference in the ARI visit rate between control clinics (10% (10 007/98 894)) and intervention clinics (10% (11 954/116 006); P = 0.89).
ARI Smart Form use
In intervention clinics, 33% (86/262) of clinicians used the ARI Smart Form at least once (Table 1) . Based on ICD-9 codes, the ARI Smart Form was used in 6% (742/11 954) of ARI visits (Table 3) . For intervention ARI visits at which the ARI Smart Form was used, the duration of form use was 8.1 (standard deviation, 5.8) minutes.
Antibiotic prescribing
In the intent-to-intervene analysis, clinicians prescribed antibiotics to 43% of patients with ARI diagnoses in control clinics and to 39% of patients with ARI diagnoses in intervention clinics (OR, 0.8; 95% CI, 0.6-1.2; P = 0.30; Table 3 ). There was no significant difference in antibiotic prescribing for antibiotic appropriate ARIs (OR, 0.8; 95% CI, 0.5-1.3) or for nonantibiotic appropriate ARIs (OR, 0.9; 95% CI, 0.6-1.4). There was also no significant difference in antibiotic prescribing between control and intervention clinics for non-ARI visits (5% in control clinics versus 6% in intervention clinics; OR, 1.1; 95% CI, 0.9-1.3) or for all visits (9% in both control and intervention clinics; OR, 1.0; 95% CI, 0.8-1.2).
In the as-used analysis, for visits in which the ARI Smart Form was used (n = 990), there was good Figure 1 Randomisation agreement between the ICD-9 diagnosis and the ARI Smart Form listed diagnosis (k, 0.54; 95% CI, 0.50-0.58). In the as-used analysis with diagnoses derived from the ARI Smart Form, antibiotic prescribing rates were 88% for antibiotic appropriate diagnoses (compared with 59% in control visits; OR, 5.0; 95% CI, 2.9-8.6), 27% for non-antibiotic appropriate diagnoses (compared with 34%; OR, 0.7; 95% CI, 0.5-1.0) and 49% for all ARI diagnoses (compared with 43%; OR, 1.3; 95% CI, 0.8-2.0). In the as-used analysis, the antibiotic prescribing rate was lower for acute bronchitis (45% vs 61%, OR, 0.5 compared to control clinics; 95% CI, 0.3-0.8).
Revisit rates
The 30-day revisit rate to study clinics for control ARI visits was 26% (2566/10 007) and for intervention visits was 23% (2765/11 954; P = 0.32). The 30-day revisit rate to study clinics attributable to ARIs was 9% (913/10 007) in control clinics and 8% (969/11 954) in intervention clinics (P = 0.29).
Discussion
We evaluated the ARI Smart Form, a documentationbased clinical decision support system, in a cluster randomised controlled trial. The point estimates for antibiotic prescribing for all ARI diagnoses, antibiotic appropriate ARI diagnoses and non-antibiotic appropriate ARI diagnoses were less than 1.0. As used, the ARI Smart Form was associated with a marginal reduction in antibiotic prescribing for non-antibiotic appropriate diagnoses and a reduction in antibiotic prescribing for acute bronchitis, one of two diagnoses that account for the majority of ARI antibiotic prescribing. 2 However, these findings were either not statistically significant or were subgroup analyses that may not generalise to the entire population making In the control group, 62 of 79 respondents said they were 'somewhat experienced' or 'very experienced' at using the electronic health record in a pre-intervention survey. In the intervention group, 80 of 113 respondents said they were 'somewhat experienced' or 'very experienced' at using the electronic health record. e ARI, acute respiratory infection f NA, not applicable ARI visits. In the primary intent-to-intervene analysis, the ARI Smart Form was not associated with improved antibiotic prescribing for ARIs overall. The main reason for this finding was the poor uptake of the ARI Smart Form.
We designed the ARI Smart Form to have self-evident value to clinicians. It was our hope that it would effectively facilitate documentation, improve workflow and provide integrated decision support. We designed the ARI Smart Form to include three of the four clinical decision support characteristics associated with improved clinical practice: provision of recommendations rather than just assessments; provision of decision support at the time and location of decision making; and computer-based decision support. 24 Why then was the ARI Smart Form used in so few visits?
First, we were missing the fourth characteristic of successful clinical decision support applications: the automatic provision of decision support as part of clinicians' workflow. 24 Clinicians had to actively invoke the ARI Smart Form from the notes page. Such voluntarily invoked applications may go unused, in part because clinicians do not think they need decision support. 25 Second, the ARI Smart Form may not have felt sufficiently integrated with the rest of the EHR. The ARI Smart Form, when invoked, appeared in a separate window, unlike other methods of documentation within the EHR. To be most effective, clinical decision support must fit as seamlessly as possible into existing workflow and allow clinicians to manage unanticipated interruptions. 21, 26 Third, the ARI Smart Form introduced new concepts in documentation for our EHR: drop-down lists, check boxes, radio buttons and automatic generation of a narrative note. Clinicians may have been turned off by what they felt was new complexity that could lead to a loss of overview, fragmentation of thinking and an overly detailed and unhelpful resulting note, 26 especially for a medical problem generally perceived to be straightforward. Fourth, the ARI Smart Form introduced a lack of flexibility. Clinicians needed to make a determination at the beginning of the visit or the beginning of documentation whether or not they were going to use the ARI Smart Form. Clinicians may have feared being 'locked-in' to using the ARI Smart Form when they were unsure whether the visit would include other problems. 26 Finally, some cliniciansour prior work would suggest about 25% -may not use the EHR at all during patient visits. 27 Even as-used, the ARI Smart Form was only associated with, at best, modest improvements in diagnostic accuracy and antibiotic prescribing. ARI Smart Form use was also associated with increased antibiotic prescribing for antibiotic appropriate diagnoses. Whether these results are due to more appropriate prescribing, better matching of diagnosis to treatment, or both is not clear. Why was the ARI Smart Form, as-used, not effective in reducing the antibiotic prescribing rate? First, there is the usual list of reasons that clinicians cite for prescribing antibiotics for predominantly viral ARIs -diagnostic uncertainty, lack of time, patient desire and fear of complications, among others -and a lack of compelling reasons for clinicians to change practice patterns. 13, 28, 29 Second, contributing to diagnostic and therapeutic uncertainty, there are competing and conflicting guidelines for some ARIs. 30 Third, providers may be concerned that the recommendations will not be applicable to their patients or will not be tolerated (i.e. because of comorbidities or contraindications). 31 Fourth, clinicians may have preferentially used the ARI Smart Form when they were going to prescribe antibiotics. Finally, there may be particular challenges to providing decision support for acute problems and errors of commission. Most decision support applications for ambulatory care have addressed errors of omission for chronic problems. 24, 32 It may be The most common diagnoses for these 248 visits were cough (36%), no diagnosis given (29%), unspecified viral infection (10%), allergic rhinitis (4%) and asthma (2%) e The most common diagnoses for these 51 visits were other diagnoses (31%), allergies (25%), cough (19%) and asthma (12%)
inherently more difficult to provide decision support that strives to have clinicians not do something in the context of a single visit than to encourage clinicians to take an action over time for a chronic problem. 21 There have been many other examples of clinical decision support implementation failures reported in the medical literature. These failures have included order entry decision support for hypertension, congestive heart failure, coronary artery disease, asthma and chronic obstructive pulmonary disease; 31, [33] [34] [35] [36] an EHR based clinical decision support system for the management of asthma and angina in primary care; 37, 38 a computer clinical decision support system to reduce cardiovascular risk for patients with hypertension; 39 and reminders for the care of chronic conditions. 40, 41 For all these failures, Samore and colleagues had notable success with introducing paper and personal digital assistant based clinical decision support to rural communities to increase the appropriateness of antibiotic prescribing for ARIs. 42 Communities that received clinical decision support had a reduction in antibiotic prescribing and clinicians in those communities reduced antibiotic prescribing for non-antibiotic appropriate diagnoses. The implementation by Samore and colleagues was extremely intensive: they reached 71% of clinicians in intervention communities; contacted pharmacies, mayors, health departments and school superintendents; and distributed thousands of posters, brochures and household mailings. This intensity of implementation was probably critical to its success.
In the future, other than the design issues addressed above, what steps could ensure that applications similar to the ARI Smart Form are used? First, the introduction and training should be more intensive. For this trial, the introduction of the ARI Smart Form was limited and weak. The lead investigator introduced the application with a single site visit at which only some of a practice's clinicians were present. This visit was followed with monthly emails to all intervention providers, but the application was not formally supported. A single visit and seven emails is probably not enough to encourage users to try a new application intended for use during patient visits. Broad programmatic support with a phased roll-out, with more intensive introduction and training at each clinic, may have been more successful. 43 Second, with such a limited and weak introduction strategy, the sevenmonth intervention period may not have allowed enough time for knowledge of the application to have diffused through the intervention clinics. Since the end of the study, with no promotion, the ARI Smart Form has been available throughout the Partners HealthCare system. From June 2006 to February 2009, over 450 clinicians used the ARI Smart Form 13 435 times and a newer paediatric version of the ARI Smart Form was used 2722 times by about 70 paediatricians. Clearly many clinicians -admittedly a minority -are finding some value in using the ARI Smart Form. Finally, our experience highlights the importance of ongoing cycles of usability testing and application refinement prior to widespread roll-out. Moving forward, we should go back to focus groups of users and non-users to find out more about what they did not like about the ARI Smart Form and make design changes. Qualitative research is critical to understanding how and why the ARI Smart Form went unused and if future modifications are worthwhile. 26, 38 Our study has several limitations that should be considered. First, our identification of ARI visits was dependent on claims diagnoses. We had previously found that claims diagnoses for ARIs were accurate, 22 but there was probably some degree of diagnostic misclassification. This is apparent in examining specific ARI diagnoses in the as-used intervention group when the diagnosis was determined using ICD-9-CM codes or the ARI Smart Form diagnosis. This also reveals another potential benefit of applications like the ARI Smart Form -improvement in documentation and coding. Second, we identified antibiotic prescribing only using the EHR. Prescriptions that were handwritten or phoned-in without EHR entry or that occurred outside the context of a visit could be missed, but we would expect this to be increasingly rare in the Partners HealthCare system. 22 Finally, the trial was conducted in academically affiliated primary care clinics using a locally developed system, possibly limiting the extent to which it can be generalised.
Conclusion
In conclusion, introduction of a documentation-based clinical decision support system for the care of patients with ARIs did not result in significant changes in antibiotic prescribing, primarily because the application went largely unused. Even as-used, the ARI Smart Form was not clearly associated with improved antibiotic prescribing. For similar applications, developers should ensure their applications are well integrated into workflow and significant resources are dedicated to implementation. To decrease inappropriate antibiotic prescribing for ARIs, many other strategies beyond clinician directed computerised clinical decision support can be employed: physician education, physician audit and feedback (including counter-detailing and use of opinion leaders), patient education, multidimensional interventions, delayed antimicrobial prescriptions and financial or regulatory incentives. [44] [45] [46] However, health information technology is likely to be part of the solution in improving quality. As ARIs are the primary reason for antibiotic prescribing, much of it inappropriate, there remains a need for scalable and effective technology interventions that decrease inappropriate antibiotic prescribing.
